Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS
Acumen Pharmaceuticals — Q3 2023 Earnings Presentation
9 slides from Acumen Pharmaceuticals's earnings presentation, Nov 13, 2023
Slide 1: Q3 2023 Financial Results & Business Update
Q3 2023 Financial Results & Business Update November 13, 2023 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and
Slide 3: Agenda
Agenda • Q3 2023 Business Update Dan O’Connell, Chief Executive Officer • ACU193 Clinical Development Update Dr. Eric Siemers, Chief Medical Officer • Q3 2023 Financial Results Matt Zuga, Chief Business Officer & Chief Financial Officer 3
Slide 4: Recent Significant Operational and Strategic Progress in ACU193 Clinical Development Program
Recent Significant Operational and Strategic Progress in ACU193 Clinical Development Program • Today, presented positive data from CSF biomarkers that is highly supportive of ACU193’s downstream pharmacological effects in the brain • Observed dose dependent trend in the multiple ascending dose cohor
Slide 5: INTERCEPT-AD: Consistent Drug Effects Observed in the Multiple Ascending Dose Cohorts
INTERCEPT-AD: Consistent Drug Effects Observed in the Multiple Ascending Dose Cohorts in the INTERCEPT-AD Trial for CSF Phospho-tau181, Total Tau, Neurogranin and the Ab 42/40 Ratio CSF biomarker changes reinforce downstream pharmacology of ACU193 in addition to the previously presented target engag
Slide 6: INTERCEPT-AD: Significant Correlation Between Change in CSF Neurogranin and pTau181
INTERCEPT-AD: Significant Correlation Between Change in CSF Neurogranin and pTau181 • Researchers in the field, such as Agnello p < 0.0001 et al and others,1,2,3 have found correlations between CSF neurogranin and pTau. • This suggests a biological link between these two biomarkers and provides furt
Slide 7: Changes in CSF Neurogranin and pTau181 More Closely Related to Target Engagement
Changes in CSF Neurogranin and pTau181 are More Closely Related to Target Engagement (Binding to Ab Oligomers) Than Plaque Reduction r = -0.433 r = -0.276 p = 0.011 p = 0.115 Engagement Target • These data are consistent with the MOA and target engagement of Reduction ACU193 Plaque • Provide evidenc
Slide 8: No Significant Drug Effect Observed on CSF Levels of Neuropentraxin 2
No Significant Drug Effect Observed on CSF Levels of Neuropentraxin 2 Additional study will be required to understand more about this relatively new biomarker 8
Slide 9: Significant Milestones Achieved in 2023
Significant Milestones Achieved in 2023 STATUS/ MILESTONES EXPECTED TIMING Proof-of-mechanism topline results ✓ ~$283M Cash, cash equivalents and marketable securities as of Biomarker results from Phase 1 study ✓ Sept 30, 2023 Anticipated interaction with FDA ✓ Up to $50M Debt financing secured from
Acumen Pharmaceuticals — Q3 2023 Earnings Presentation on 6ix